Csl Limited

Summary

Introduction

CSL is a global, specialty biopharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products of biological origin such as vaccines and plasma protein biotherapies. It operates globally through its human health businesses that include the operations of CSL Behring, CSL Bioplasma and CSL Biotherapies, as well as new product development activities.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

CSL's product portfolio includes more than 150 products that are marketed worldwide. The products are offered through its human health businesses that include the operations of CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma. CSL derives its revenues primarily from the products offered through its three subsidiaries: CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma. In addition, the group receives royalties from Merck, its licensee, on the sales of Gardasil for which Merck has exclusive global marketing rights. The group's major contributor to the revenues during 2002-2006 was product sales that include revenues from the sales of pharmaceutical products of biological origin such as vaccines and plasma protein biotherapies. Product sales increased from $971 million in 2003 to $2,126 million in 2006.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content